Lucid Diagnostics Inc.
LUCD · Surgical & Medical Instruments & Apparatus · 203.1M shares · +15%/yr ↑ shares · EDGAR filings ↗
Reference price $1.00 · est. market cap ~$203M — last insider purchase, 2026-05-20 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Medical-device company (the EsoGuard esophageal-cancer test) with operating losses and cash burn.
Strengths
- Liquidity — current ratio 1.3 (23rd)
Risks
- Operating/net losses & cash burn — per metrics
- deep losses and thin liquidity — per 10-K
- Adoption/reimbursement dependence — per 10-K
Notable findings
- Going concern● We have concluded there is substantial doubt of our ability to continue as a going concern and our independent registered public accounting firm’s report on our financial statements contains an ex
- Cash burnNegative free cash flow (-46.7M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, CITADEL ADVISORS LLC
- Chronic dilutionShare count +15%/yr over 1y (dilution)
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$245,270, last 6mo) Form 4 ↗
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-530.4%
Return on assets
-143.4%
Revenue growth (QoQ)
4.1%
Current ratio
1.3×
Free cash flow
-$47M
EBITDA
-$49M
Tangible book value
$11M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | Matheis Dennis | Buy | 245K | $1.00 |
| 2026-02-20 | Aklog Lishan | Grant | 2.2M | — |
| 2026-02-20 | Matheis Dennis | Grant | 123K | — |
| 2026-02-20 | White Debra | Grant | 123K | — |
| 2026-02-20 | Sparks Ronald M | Grant | 123K | — |
| 2026-02-20 | SOKOLOV JACQUE J | Grant | 123K | — |
| 2026-02-20 | PALUMBO JOHN R | Grant | 123K | — |
| 2026-02-20 | Cox James L | Grant | 123K | — |
| 2026-02-20 | MCGRATH DENNIS M | Grant | 470K | — |
| 2026-02-20 | O'Neil Shaun | Grant | 620K | — |
| 2026-02-20 | Gordon Michael Adam | Grant | 300K | — |
| 2026-02-20 | Lapidus Stanley | Grant | 123K | — |
| 2025-08-20 | Matheis Dennis | Buy | 100K | $1.02 |
| 2025-05-22 | Matheis Dennis | Buy | 33K | $1.32 |
| 2025-05-22 | Matheis Dennis | Buy | 33K | $1.32 |
| 2025-05-21 | Matheis Dennis | Buy | 130K | $1.32 |
| 2025-05-21 | Matheis Dennis | Buy | 130K | $1.32 |
| 2025-05-20 | Matheis Dennis | Buy | 187K | $1.29 |
| 2025-05-20 | Matheis Dennis | Buy | 187K | $1.29 |
| 2025-02-20 | Aklog Lishan | Grant | 300K | — |
| 2025-02-20 | SOKOLOV JACQUE J | Grant | 113K | — |
| 2025-02-20 | Lapidus Stanley | Grant | 113K | — |
| 2025-02-20 | Sparks Ronald M | Grant | 113K | — |
| 2025-02-20 | Cox James L | Grant | 113K | — |
| 2025-02-20 | MCGRATH DENNIS M | Grant | 300K | — |
| 2025-02-20 | Gordon Michael Adam | Grant | 300K | — |
| 2025-02-20 | White Debra | Grant | 113K | — |
| 2025-02-20 | Matheis Dennis | Grant | 113K | — |
| 2025-02-20 | O'Neil Shaun | Grant | 300K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06030180 ↗ | CLUE: CLinical Utility Study of EsoGuard Barrett Esophagus, Barretts Esophagus With Dysplasia | NA | Completed | 2024-12-13 |
| NCT05778851 ↗ | Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population Barrett Esophagus | NA | Completed | 2024-07-31 |
| NCT05965999 ↗ | Lucid Registry Study Barrett Esophagus, Esophageal Adenocarcinoma | — | Unknown | 2024-06-01 |
| NCT04295811 ↗ | Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC Barrett Esophagus, Esophageal Adenocarcinoma | NA | Unknown | 2023-12-01 |
| NCT04293458 ↗ | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE Barrett Esophagus, Esophageal Adenocarcinoma | NA | Completed | 2022-08-22 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-24 | 5.03Shareholder voteExhibits | filing ↗ |
| 2026-05-14 | ResultsReg FDExhibits | filing ↗ |
| 2026-04-24 | Reg FDOtherExhibits | filing ↗ |
| 2026-04-23 | Material agreementReg FDExhibits | filing ↗ |
| 2026-03-26 | ResultsReg FDExhibits | filing ↗ |
| 2025-11-12 | ResultsReg FDExhibits | filing ↗ |
| 2025-09-25 | Exec/director changeReg FDExhibits | filing ↗ |
| 2025-09-11 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-24 | 2026-06-24 | 0001493152-26-029943 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001493152-26-022877 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001437749-26-016751 ↗ |
| 8-K | 2026-04-24 | 2026-04-24 | 0001493152-26-018926 ↗ |
| 8-K | 2026-04-23 | 2026-04-23 | 0001493152-26-018725 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001493152-26-012807 ↗ |
| 10-K | 2026-03-25 | 2025-12-31 | 0001437749-26-009805 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001493152-25-021748 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001493152-25-021737 ↗ |
| 8-K | 2025-09-25 | 2025-09-22 | 0001493152-25-014872 ↗ |
| 8-K | 2025-09-11 | 2025-09-11 | 0001493152-25-013046 ↗ |
| 8-K | 2025-09-10 | 2025-09-10 | 0001493152-25-012962 ↗ |